News coverage about Adverum Biotechnologies (NASDAQ:ADVM) has been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3101422493727 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Zacks: Analysts Expect Adverum Biotechnologies, Inc. (ADVM) Will Post Earnings of -$0.36 Per Share (americanbankingnews.com)
- Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update – GlobeNewswire (press release) (globenewswire.com)
- Adverum Biotechnologies, Inc. (ADVM) Posts Earnings Results, Misses Expectations By $0.03 EPS (americanbankingnews.com)
- Adverum Biotechnologies posts 3Q loss (finance.yahoo.com)
Adverum Biotechnologies (NASDAQ:ADVM) opened at $3.00 on Tuesday. Adverum Biotechnologies has a 52 week low of $2.40 and a 52 week high of $4.20.
Adverum Biotechnologies (NASDAQ:ADVM) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). The company had revenue of $0.46 million for the quarter. Adverum Biotechnologies had a negative net margin of 3,398.29% and a negative return on equity of 26.60%. equities research analysts anticipate that Adverum Biotechnologies will post -1.31 earnings per share for the current fiscal year.
A number of equities analysts recently commented on the stock. ValuEngine lowered shares of Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 9th. Raymond James Financial, Inc. assumed coverage on shares of Adverum Biotechnologies in a research note on Thursday, October 12th. They issued an “outperform” rating and a $6.00 price objective for the company. Zacks Investment Research lowered shares of Adverum Biotechnologies from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $3.50 price objective on shares of Adverum Biotechnologies in a research note on Tuesday, September 5th.
ILLEGAL ACTIVITY NOTICE: “Adverum Biotechnologies (ADVM) Receives News Sentiment Score of 0.16” was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.truebluetribune.com/2017/11/14/adverum-biotechnologies-advm-receives-news-sentiment-score-of-0-16.html.
Adverum Biotechnologies Company Profile
Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.
Receive News & Ratings for Adverum Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.